NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study

Table 4 Relation of NFS and PCSK9 levels with MACEs in all patients

	Events/subjects	Model 1		Model 2
	Events/subjects	HR(95%CI)	p	HR(95%CI)	p
NFS
per 1-SD increase	158/2008	1.353 (1.154,1.586)	< 0.0001	1.222 (1.027,1.453)	0.024
Low	45/798	1.0		1.0
Intermediate	93/1072	1.516 (1.062,2.164)	0.022	1.245 (0.859,1.804)	0.248
High	20/138	2.561 (1.511,4.341)	< 0.0001	1.935 (1.107,3.381)	0.020
PCSK9
per 1-SD increase	158/2008	1.277 (1.097,1.486)	0.002	1.224 (1.047,1.431)	0.011
Low	37/669	1.0		1.0
Intermediate	54/670	1.499 (0.985,2.281)	0.059	1.366 (0.894,2.087)	0.149
High	67/669	1.850 (1.229,2.784)	0.003	1.683 (1.109,2.554)	0.014
PCSK9 + NFS	158/2008
Low PCSK9 + low NFS	9/297	1.0		1.0
Low PCSK9 + intermediate-high NFS	28/372	2.399 (1.132,5.085)	0.022	1.948 (0.914,4.151)	0.084
Intermediate PCSK9 + low NFS	15/258	1.986 (0.869,4.540)	0.104	1.802 (0.783,4.147)	0.166
Intermediate PCSK9 + intermediate-high NFS	39/412	3.237 (1.568,6.685)	0.001	2.369 (1.134,4.951)	0.022
High PCSK9 + low NFS	21/243	2.966 (1.357,6.486)	0.006	2.689 (1.219,5.934)	0.014
High PCSK9 + intermediate-high NFS	46/426	3.677 (1.792,7.546)	< 0.0001	2.693 (1.295,5.599)	0.008

NFS non-alcoholic fatty liver disease fibrosis score, PCSK9 proprotein convertase subtilisin/ kexin type 9, MACEs major adverse cardiovascular events, HR hazard ratio, CI confidence interval. Model 1 was adjusted for age and gender, except NFS (only adjusted for gender). Model 2 was adjusted for model 2 covariates plus body mass index, hypertension, family history of coronary artery disease, coronary artery disease, diabetes, smoking, drinking, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose, hemoglobin A1c, antiplatelet drugs, antihypertensive drugs. p < 0.05 suggests significant difference

ISSN: 1476-511X